A Randomized, Open-Label, Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy for the First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor Aberrations
Study Number: GS-US-626-1126
Study Summary:
The primary objective of this study is to compare the effect of zimberelimab (ZIM) and domvanalimab (DOM) in combination with chemotherapy relative to pembrolizumab (PEMBRO) in combination with chemotherapy on progression-free survival (PFS) and overall survival (OS) in patients with untreated metastatic non-small cell lung cancer with no actionable genomic alteration.
Status: Open
Study Coordinator(s)
- Navigator Ashton, 309-243-3611 atodd@illinoiscancercare.com
- Amanda , 309-243-3663, amullery@illinoiscancercare.com
- Jessica, 309-243-3615, jjones@illinoiscancercare.com
